SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is actively discussed following its recent earnings report, which saw revenue exceed expectations but a reduced profit outlook for upcoming quarters, sparking a significant sell-off. The community is divided, with many attributing the decline to broader "AI panic" impacting software, while others see it as an attractive long-term buying opportunity for a leading cybersecurity firm.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as news emerges of NVIDIA reportedly exiting its stake, sparking a divided community response with some citing a loss of confidence while others view it as an overreaction given APLD's core AI infrastructure business and upcoming contracts.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending following a landmark joint venture with Americas Gold and Silver to establish North America's first commercial hydrometallurgical processing facility for critical minerals, a move seen as vital for strengthening domestic supply chains. The community, however, is actively discussing widespread frustration over the stock's price action, attributing it to persistent market manipulation despite the overwhelmingly positive news and analyst upgrades.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as major hyperscalers like Google and Amazon unveil massive capital expenditure plans for AI infrastructure, positioning the company as a key beneficiary for its custom AI accelerators and networking solutions. The community is actively discussing its undervalued status and significant growth potential, particularly with strong AI revenue expectations for its upcoming earnings report.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is gaining attention as it advances microreactor development, highlighted by commencing drilling for its KRONOS system and expanding through a recent Canadian acquisition and South Korean partnership, fueling community discussions about its potential to meet the surging energy demands of AI data centers amidst broader nuclear sector tailwinds.

Fiverr International Ltd. develops an e-commerce platform that allows people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.

Fiverr International Ltd

Fiverr is trending due to its recent earnings report, which saw an EPS beat but a revenue miss, coupled with an organizational restructuring plan focusing on AI and an expanded share repurchase program. This has fueled a heated debate among investors regarding whether the company is a deeply undervalued, profitable gem adapting to AI, or an obsolete business facing existential threats from AI competition and a shrinking buyer base.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger (QRL) is trending as accelerating quantum computing advancements fuel growing market concerns over the future security of traditional cryptocurrencies, positioning QRL as a vital quantum-resistant hedge. The community is actively discussing QRL's upcoming 2.0 upgrade to introduce post-quantum smart contracts, alongside recent platform listings and OTC service availability, as key catalysts for its role in securing digital assets against emerging quantum threats.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

A deep stock decline driven by conservative 2026 revenue guidance for DefenCath, stemming from the upcoming expiration of its key transitional reimbursement status, has ignited strong investor criticism of CEO leadership and fueled concerns about market manipulation, despite a newly announced share buyback program.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending on news of Meta Platforms significantly expanding its multi-year AI infrastructure partnership with a commitment to millions of advanced chips, alongside a major investment in an Indian AI supercluster using NVIDIA technology. The community is actively discussing the company's sustained dominance in the foundational AI infrastructure layer amid accelerating global demand.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending amidst a broader AI sector sell-off, with community discussion focused on its upcoming Q4 earnings report and its potential to clarify recent volatility. Many investors are evaluating the current price as a strategic buying opportunity, citing partnerships with Palantir and expansion into government AI and robotics, while others express concern over the stock's performance despite positive developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday.</li><li>Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October.</li><li>Retail sentiment flipped to ‘extremely bullish’ from ‘extremely bearish’ on Stocktwits, and message volume surged more than 900%.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. jumped 11% on Tuesday, marking the stock’s biggest rally in over a month, after a biotech-focused investment firm rebuilt its stake amid heightened buzz among retail traders speculating a possible takeover.<h2 class="st-heading-2">Cormorant Lifts MoonLake Stake Above 6%</h2>A Schedule 13G filing on Tuesday showed Cormorant Asset Management reported ownership of 4.36 million Class A ordinary shares in MoonLake Immunotherapeutics, representing a 6.1% stake as of Dec. 31, 2025. The stake increased from about 2 million shares, or 3.14%, disclosed in October 2025 filings, after the firm had previously reduced its position below the 5% reporting threshold.Cormorant Asset Management is a biotech-specialised investment management firm with stakes in Praxis Precision Medicines, BridgeBio Oncology Therapeutics, Edgewise Therapeutics, and Metsera, which was acquired last year by Pfizer, among others.According to data from Quiver Quantitative, the firm reported holdings in 43 stocks as of Sept. 30, 2025, with an estimated portfolio value of about $1.45 billion.<h2 class="st-heading-2">FDA Momentum Builds Around Sonelokimab</h2>Earlier this month, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s lead investigational therapy, Sonelokimab, for moderate-to-severe palmoplantar pustulosis. The company plans to pursue a biologics license application for Sonelokimab in hidradenitis suppurativa in the second half of 2026.Last month, MoonLake said a Type B meeting with the FDA confirmed its clinical evidence strategy for Sonelokimab in hidradenitis suppurativa. Following that update, several brokerages raised price targets or upgraded the stock, though&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-erases-most-of-2025-loses-wall-street-retail-bets-on-fda-feedback-for-sonelokima/cmU1QhGR471">Goldman Sachs</a> downgraded MoonLake to ‘Sell’ last month, citing “high risk” around approvability in hidradenitis suppurativa.The company is scheduled to host an investor day on Feb. 23, at which it plans to provide updates on the clinical development and regulatory pathway for Sonelokimab across multiple inflammatory disease indications.<h2 class="st-heading-2">Stocktwits Buzz Erupts Around MLTX</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘extremely bullish’ from ‘extremely bearish’ over the past day amid over a 900% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_b0740594f9.webp" alt="mltx ss.png" width="971" height="140"><figcaption>MLTX sentiment and message volume as of February 17 | Source: Stocktwits</figcaption></figure>One user said the Cormorant filing has “fundamentally broken” the short thesis. “Cormorant—who knows the science better than anyone—just admitted the "Bear Thesis" was wrong by buying back in at $12-$16.”<stembedurl>https://stocktwits.com/septrading/message/645184471</stembedurl>Another user said, “I can’t stop thinking that we get a PR of some sort, even a little teaser, PM tomorrow AM” ahead of the company’s investor day.<stembedurl>https://stocktwits.com/BOOPIE2020/message/645177386</stembedurl>A third user said, “I have to say that something may be coming..This price action today was solid coupled with the high after hours volume. Someone is accumulating.”<stembedurl>https://stocktwits.com/TDMF123/message/645174457</stembedurl>A separate user said they were watching for either a buyout announcement or positive regulatory news this week, while another argued MoonLake would need to trade higher before attracting interest from a large pharmaceutical acquirer.<stembedurl>https://stocktwits.com/Warren_8/message/645090086</stembedurl><stembedurl>https://stocktwits.com/Newcar/message/645134185</stembedurl>One user pointed to recent travel activity involving Merck’s corporate jet, hinting at a potential takeover by the big pharma firm and noted multiple trips to Zurich, where MoonLake is headquartered.&nbsp;<stembedurl>https://stocktwits.com/Bigpapa46/message/645006814</stembedurl>MLTX stock has risen 33% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Equity

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00

HC Wainwright upped their price objective on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday...

BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer

Oppenheimer boosted their price target on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Friday...

Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an "overweight" rating in a research note on Friday...

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High - Here's What Happened

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High - What's Next...

BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia

BridgeBio Pharma (NASDAQ:BBIO) detailed positive Phase 3 results from its PROPEL-3 clinical trial evaluating oral infigratinib for children with achondroplasia, describing what executives called...

<ul class="summary-bullets"><li>The study met its main goal by demonstrating a meaningful increase in annualized height velocity compared with placebo.&nbsp;</li><li>Secondary measures reinforced those results, including improvements in absolute growth rate and height Z-scores relative to achondroplasia norms.</li><li>BridgeBio said it intends to meet with regulators to discuss filing a New Drug Application in the U.S.</li></ul>BridgeBio Pharma Inc. (BBIO) on Thursday reported encouraging phase-3 study data for its experimental oral therapy infigratinib, saying the drug improved growth outcomes in children with achondroplasia, a genetic form of dwarfism.&nbsp;The topline findings stem from PROPEL 3, a global, yearlong Phase 3 trial that enrolled children ages 3 to younger than 18 with open growth plates. Participants were randomly assigned at a 2:1 ratio to receive infigratinib or placebo, with statistically significant improvements across key growth measures through Week 52.<h2 class="st-heading-2">Primary And Secondary Endpoints</h2>The study met its main goal by demonstrating a meaningful increase in annualized height velocity compared with placebo. Children receiving the therapy grew faster on average, with a treatment benefit of more than 2 centimeters per year compared with placebo.&nbsp;Secondary results supported the primary findings, including improvements in absolute growth rate and height scores relative to achondroplasia norms. The company said the magnitude of improvement ranks among the strongest seen in randomized studies for the condition.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/BBIO">BridgeBio Pharma's stock</a> traded over 17% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘neutral’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Body Proportionality Findings&nbsp;</h2>In an analysis of children younger than 8, infigratinib also achieved a statistically significant improvement in upper-to-lower body proportionality compared with placebo.&nbsp;<blockquote>“In the broadest age range studied to date, oral infigratinib has demonstrated the highest and most significant improvement in annualized growth velocity, along with the first statistically significant improvement in body proportionality, in children aged 3 to 8 years, reported for any therapy approved or in development for this condition.”-Ravi Savarirayan, Global Lead Investigator, PROPEL 3</blockquote>BridgeBio said it intends to meet with regulators to discuss filing a New Drug Application in the U.S. and a Marketing Authorization Application in Europe in the second half of 2026.BBIO stock has gained over 129% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/the-big-short-investor-michael-burry-reflects-on-palantir-s-billions-in-losses-before-2020-debut/cZRTNcbR4rL">‘The Big Short’ Investor Michael Burry Reflects On Palantir’s Billions In Losses Before 2020 Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally?

The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism. 

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BBIO News

BBIOBridgeBio Pharma Inc